Jounce Therapeutics Inc. (JNCE): Technical Analysis and analyst Ratings


Jounce Therapeutics Inc. (NASDAQ:JNCE) changes shares on Friday trading session, with a change of 3.10% or $0.19 shares. The trading starts at $6.22 and closed at $6.13 throughout the day. The trading session low price was $6.12 and day high was $6.432 on Friday, June 19. After the session, the Healthcare sector daily volume shifted to 0.25 million while its average volume is 282.55K. In other hand, the JNCE market cap reached to $208.69M.

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is up 13.67% and up 24.90% for month. Its quarterly performance was 62.47% above, while its half year performance is down -20.90%. JNCE yearly performance stood at positive 33.33% and fall -27.61% for year-to-date. Current recommendation for Jounce Therapeutics Inc. is 2.30.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. JNCE EPS (TTM) for 12-month is 1.23. EPS for this year is 297.10%, while for the next year its value is -2.52. Its EPS Q/Q reached -106.90%. It has an EPS of 43.00% up for past five years.

TRV GP II, LLC, TRV GP III, LLC and Blackrock Inc. are the top three holders in Jounce Therapeutics Inc. (JNCE) stock. On Mar 30, 2020, TRV GP II, LLC has 10.23 million shares which valued 48.59 million. On Mar 30, 2020, TRV GP III, LLC owned 3.05 million shares which valued at 14.48 million. On Mar 30, 2020, Blackrock Inc. has a total of 1.24 million shares which valued at 5.9 million. In the end, Blackrock Inc. have 3.65% shares outstanding of Jounce Therapeutics Inc. (JNCE) on Mar 30, 2020. The insider ownership moved to 1.10% and institutional holding shifted to 76.40%.

The company posted an EPS (TTM) of 1.23. According to the most recent quarter report on (Jun 2020), 6 analysts estimated an average EPS of -0.72, while -0.21 EPS posted a year ago period. Analyst Estimated EPS for JNCE published in the report was -0.8–0.64 during the same period. Comparing with last year, the average estimated EPS was -0.21 which is higher than -0.78 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for JNCE rise 19.99% for period of 200 days. SMA for 50 days was 20.83% which is showing green signal, while SMA-20 was 10.02%. The moving average value for Jounce Therapeutics Inc. (JNCE) is 5.89 and 5.44 for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in JNCE stock. On Jan 07, Trehu Elizabeth, Chief Medical Officer, sold 2,624 trading shares at the cost of $7.78, which valued at 20415.0. On Jan 07, Drapkin Kimberlee C, CFO and Treasurer, sold 2,624 shares at the cost of $7.78, with total shares of 44,390. On Jan 07, Cole Hugh M, Chief Business Officer, sold 2,624 shares at the cost of 7.78. After this transaction, Cole Hugh M total shares reached to 33,590 which valued at 20415.0.